Teva

CompanyIsraelFounded 1901

RORWikidata

Teva develops 12 assets, the furthest approved (glatiramer acetate in clinically isolated syndrome). Mostly small molecule and peptide acting on AVPR1A, AVPR1B and AVPR2; based in Israel, founded in 1901.

12
Assets
Furthest stage
Approved
202
Trials
46
Signals

Pipeline

12
  • glatiramer acetate

    Modulates immune responses to myelin, reducing inflammatory damage in multiple sclerosis.

    Approved, Peptide, clinically isolated syndrome, Relapsing Forms of Multiple Sclerosis

  • Losartan potassium/Hydrochlorothiazide

    Angiotensin II receptor antagonist combined with a thiazide diuretic to lower blood pressure.

    Approved, Small molecule, hypertension, left ventricular hypertrophy

  • MINIRIN

    Activates vasopressin V2 receptors to increase renal water reabsorption and reduce urine production.

    Approved, not sold in the US, Peptide, AVPR1A, AVPR1B, nocturia (Phase 3), nocturnal enuresis (Phase 3)

9 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms9
  • Trials273
  • Signals20
  • Similar companies6

Papers

Intelligence